Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On January 25, 2023 and effective as of March 1, 2023, the Board of Directors (the "Board") of Kinnate Biopharma Inc. (the "Company") appointed Jill DeSimone to the Board. Ms. DeSimone will serve as a Class II director, with a term expiring at the Company's 2025 annual meeting of the stockholders, and serve as a member of the Audit Committee and Compensation Committee of the Board.

In accordance with the Company's Outside Director Compensation Policy (the "Director Compensation Policy"), a copy of which was filed as Exhibit 10.14 to the Company's Registration Statement on Form S-1/A (File No. 333-250086) filed with the SEC on November 30, 2020, Ms. DeSimone is eligible to participate in the Company's standard compensation arrangements for non-employee directors which consists of cash and equity compensation for service on the Board and, if applicable, committees of the Board. Pursuant to the Director Compensation Policy, Ms. DeSimone is entitled to $35,000 in annual cash compensation for service on the Board, $7,500 in annual cash compensation for service on the Audit Committee and $5,000 in annual cash compensation for service on the Compensation Committee. In addition, in accordance with the Director Compensation Policy, upon her appointment to the Board, Ms. DeSimone will be automatically granted an initial stock option to purchase 40,501 shares of the Company's common stock under the Company's 2020 Equity Incentive Plan. One thirty-six (1/36th) of the shares subject to this stock option will vest on a monthly basis beginning on April 1, 2023 and subject to Ms. DeSimone's continued service through each vesting date in accordance with the Director Compensation Policy.

The Company will enter into its standard form of indemnification agreement with Ms. DeSimone, a copy of which was filed as Exhibit 10.1 to the Company's Registration Statement on Form S-1 (File No. 333-250086) filed with the SEC on November 13, 2020.

There is no arrangement or understanding between Ms. DeSimone and any other person pursuant to which Ms. DeSimone was selected as a member of the Board, and Ms. DeSimone is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

A copy of the Company's press release announcing the appointment of Ms. DeSimone as a director is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.





  (d) Exhibits



Exhibit No.   Description

  99.1        Press Release dated January 26, 2023.

104           Cover page interactive data file (embedded within the inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses